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The expression of unusual glycan structures is a hallmark of cancer progression,
and their functional roles in cancer biology have been extensively investigated in epithe-
lial-to-mesenchymal transition (EMT) models. EMT is a physiological process involved in 
embryonic development and wound healing. It is characterized by loss of epithelial cell 
polarity and cell adhesion, permitting cell migration, and thus formation of new epithelia. 
However, this process is unwanted when occurring outside their physiological limit, 
resulting in fibrosis of organs and progression of cancer and metastasis. Several studies 
observed that EMT is related to the acquisition of multidrug resistance (MDR) phenotype, 
a condition in which cancer cells acquire resistance to multiple different drugs, which 
has virtually nothing in common. However, although some studies suggested interplay 
between these two apparently distinct phenomena, almost nothing is known about 
this possible relationship. A common pathway to them is the need for glycosylation, a 
post-translational modification that can alter biological function. Thus, this review intends 
to compile the main facts obtained until now in these two areas, as an effort to unravel 
the relationship between EMT and MDR.
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iNTRODUCTiON
One of the major difficulties faced by physicians in any area of medicine is the inability to prevent 
disease relapse. Unfortunately, this is a common event in several types of cancer, even in those 
where chemotherapy appeared initially effective. The acquisition of resistance to diverse chemo-
therapeutic agents by tumor cells is known as multidrug resistance (MDR) phenotype and is still 
the major cause of death in patients with small cell lung cancer, breast cancer, ovarian cancer, 
acute leukemia, and others, despite major advances in cancer chemotherapy. For decades, clinical 
oncologists and researchers dealt with the phenomenon without recognizing its causes.
In 1970, Biedler and Riehm observed that actinomycin-D-resistant Chinese hamster lung 
cells and P388 leukemia cells were cross-resistant to vinblastine and daunomycin (1). Soon other 
groups showed that this phenotype lead to resistance to several other amphiphilic compounds, but 
the phenomenon remained unexplained, until the group of Ling, in 1976, showed that the MDR 
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phenotype of Chinese hamster ovary cells selected for resistance 
to colchicine was due to a membrane alteration that reduced the 
rate of intracellular drug saturation. They demonstrated that 
those drug-resistant cells retained a cell surface glycoprotein of 
170  kDa, which was not observed in wild-type cells (2). Since 
this glycoprotein was present only in cells displaying altered drug 
permeability, it was named P-glycoprotein (P-gp), ushering in a 
new era for cancer and chemotherapy researches.
Epithelial cells are usually organized as single or multiple 
layers of single filed sheets of uniform cells. The individual cells 
are highly polarized along their base–apex axis and connect 
to each other through multiple adhesion molecules, insur-
ing the integrity and function of tissues. On the other hand, 
mesenchymal cells exhibit higher mobility, a significantly lower 
degree of organization, and no axis polarization. Epithelial-to-
mesenchymal transition (EMT) represents a number of changes 
an epithelial cell must undergo to gain a mesenchymal phenotype. 
While this model is of paramount importance in several physi-
ological situations, such as embryogenesis and wound healing, 
the type 3 EMT is well known for its role in cancer invasiveness 
and metastasis (3–5).
The most important changes that occur during EMT are the 
loss of E-cadherin with the concomitant increase in N-cadherin 
expression and metalloproteinases, such as MMP-2 and MMP-9, 
and increased translocation of β-catenin to the nucleus (6–8). 
These changes in protein expression are well studied and very 
much established as important markers for EMT (9–11).
Although there are lot of evidence supporting the role and 
importance of glycosylation in the acquisition of drug resistance 
phenotype (12–15) and during the EMT process (16–20), no 
work has yet demonstrated how the changes in glycosylation 
may connect these two multifactorial events. Previous studies 
revealed that TGF-β1, a known EMT inducer (21), as well as 
the overexpression of Twist (22), a transcription factor able to 
activate the EMT program (4), promote the appearance of breast 
epithelial cells with cancer stem cell (CSC) markers (CD44high/
CD24low). Furthermore, Liang and coworkers demonstrated that 
the emergence of such phenotype was accompanied by changes 
in the expression of mono- (GM2) and disialylated (GD1a, GD2, 
and GD3) gangliosides (22). These groundbreaking studies 
suggest that such differences in cell surface glycosylation may 
be further used as a therapeutic strategy to combat the advent 
of CSC, which, besides having potential for initiating tumor 
growth (23), is also resistant to a wide diversity of antineoplastic 
agents (24).
It is important to highlight that epigenetic events, which are 
somatically inherited through cell division, are potential drivers 
of acquired drug resistance in cancer (25, 26). The high rate of 
epigenetic changes in cancer cells generates diversity in gene 
expression patterns that can quickly evolve through drug selec-
tion during treatment, leading to the development of acquired 
resistance (27, 28).
This review will summarize studies about MDR, with a focus 
on ATP-binding cassette (ABC) transporters, EMT, glycosyla-
tion, and the possible relationship among these mechanisms in 
cancer. We will also discuss epigenetic factors related to MDR 
phenotype.
THe MULTiDRUG ReSiSTANCe 
PHeNOTYPe
Much has happened since the discovery that P-gp and other active 
membrane transporters were shown to be involved in multidrug 
resistance. In 1990, a 95-kDa membrane protein responsible 
for anthracycline resistance in MCF-7/AdrVp(100) cells was 
described (29). Furthermore, using the same cell line, this protein 
was cloned by Doyle et al. (30), who termed it as breast cancer 
resistance protein (BCRP). In 1992, another glycoprotein highly 
expressed in doxorubicin-resistant H69AR cells was identified, 
cloned, and named multidrug resistance-associated protein 
(MRP) (31).
At that moment, it became clear that those proteins shared 
some sequential and functional homology, and all belonged to the 
ABC superfamily of proteins (32). The ABC proteins are P-type 
membrane ATPases, which display two highly conserved amino 
acid sequences located in their nucleotide-binding domain, the 
Walker A and Walker B motifs, separated by the “ABC signature” 
motif LSGGQQ/R/KQR (33). With the discovery of several new 
transporters allocated in the same superfamily, came the need 
for a simplified nomenclature and thus, P-gp is now referred as 
ABCB1, BCRP as ABCG2, and MRP as ABCC1. The inventory of 
human ABC genes contains 49 isolated and identified elements, 
and it is now known that there are several more ABC proteins, 
especially from the ABCC subfamily, which are involved in 
multidrug resistance (34).
Despite the importance of the ABC proteins in MDR, other 
factors are involved in acquired or constitutive MDR phenotype. 
A factor that must be considered is the balance between the 
expression of pro- and anti-apoptotic proteins, responsible for 
tipping the scale toward cell death or survival. Overexpression 
of anti-apoptotic proteins, such as Bcl-2, Bcl-xL, and other 
anti-apoptotic members of the Bcl-2 family (35, 36), reduced 
expression of pro-apoptotic proteins, such as p-53 (37, 38) 
and Bax, which are activated by caspase 8 and responsible for 
permeabilization of the mitochondrial membrane (39, 40), as 
well as alterations in proteins and extracellular matrix adhesion 
as integrin-linked kinase (ILK) and αVβ3 integrin (41, 42) are 
some of the many factors that may contribute to chemotherapy 
resistance (43). Figure 1 shows some of the main mechanisms 
involved in MDR phenotype (44–50).
Since the presence of one or more of those ABC proteins in cell 
membranes is sufficient to trigger the MDR phenotype, they are 
heavily studied worldwide.
ABC PROTeiNS ReLATeD TO MDR: 
THe GLYCAN CONNeCTiON
The ABC proteins related to MDR phenotype are glycopro-
teins; nevertheless, little is known about the importance of 
glycosylation for their transport activity. During glycosylation, 
the sugar residues are covalently bound to the protein at 
asparagine residues for N-linked, or at serine, or threonine for 
O-linked glycans (51). The three main ABC proteins related to 
MDR: ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP) 
undergo N-linked glycosylation (Figure  2). The most studied 
FiGURe 1 | Proposed classical and cell adhesion-mediated mechanisms for MDR phenotype in cancer cells. The main mechanisms involved in classical 
acquired MDR are (1) reduced drug accumulation, mediated by ABC transporters; (2) changes in drug targets, such as variations in the expression or mutations of 
topoisomerase II; (3) increased activity of enzymes involved in DNA repair mechanisms, such as O-6-methylguanine DNA methyltransferase (MGMT); and (4) altered 
apoptotic signaling, due to mutations in the Bcl-2 family proteins, for instance. Concerning adhesion-dependent mechanisms, also four categories are described: 
(1) cancer cells can enter a low proliferation state, promoting resistance against drugs affecting the cell cycle, such mechanism could be dependent on E-cadherin 
adhesion and the cyclin-dependent kinase p27Kip1; (2) cell adhesion mediates changes in the localization of drug targets, such as topoisomerase II, which can be 
translocated to the cytoplasm via an integrin β1-dependent pathway; (3) cell adhesion alters apoptosis signaling pathways. One example is the activation of NF-κB 
through fibronectin adhesion; and (4) the linker of nucleoskeleton and cytoskeleton (LINC) complex is responsible for binding the nuclear matrix and the 
cytoskeleton, influencing gene expression, cell morphology, and signal transduction.
FiGURe 2 | Structure of the three main ABC transporters (ABCC1, ABCB1, and ABCG2), including transmembrane loops and their glycosylation sites.
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is ABCB1 or P-glycoprotein, the first protein to be related 
to the MDR phenotype. This protein is commonly found in 
cell membranes, but it may be also present at the surface of 
intracellular organelles, such as the nuclear envelope and 
lysosomes (52, 53). The human ABCB1 protein contains 10 
consensus sequences for N-linked glycosylation, but only three 
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of them (N91, N94, and N99), located at the first extracellular 
loop, are glycosylated. A recent study showed that the topotecan-
resistant- and doxorubicin-resistant human ovary carcinoma 
cell line show ABCB1 expression in both nuclear and plasma 
membranes, but tunicamycin-treated cells show ABCB1 mainly 
in the cytoplasm. It seems that tunicamycin, along with other 
N-glycosylation inhibitors, is capable of impairing the activity 
of ABC transporters by affecting its cellular localization (13). 
This protein is synthesized as a 140- to 150-kDa protein, and 
the pathways involved in its glycosylation are still not clear. It 
has been proposed that the 150-kDa protein is associated with 
chaperones calnexin and Hsc70 in the endoplasmic reticulum 
(ER) lumen. Then, ABCB1 moves from cis to trans Golgi, under-
going final steps of the N-glycosylation. After maturation, the 
protein can be delivered to the membrane in vesicles that move 
on the cytoskeleton or by an intracellular endosomal system, 
and transported to the membrane and other cell organelles, 
including the nucleus (54, 55).
In 1993, Schinkel et  al. investigated the significance of the 
conserved N-glycosylation sites present in the putative first extra-
cellular loop of ABCB1. The authors mutated one, two, or all three 
sites. They observed that the absence of N-glycosylation did not 
alter the level nor the pattern of cross-resistance but dramatically 
reduced the efficiency with which drug-resistant clones could be 
generated, suggesting that N-glycosylation contributes to proper 
routing or stability of the protein but not to drug transport itself 
(54). Two years later, Kramer et al. showed that tunicamycin sup-
pressed ABCB1 activity, observing accumulation of cytostatic 
drugs into the cells (56).
Draheim et al. (57) used sandwich-cultured rat hepatocytes to 
characterize the expression and maturation of ABCB1, ABCC2 
(MRP2), and ABCG2 proteins, as well as their transport function, 
over several days. They observed that only fully N-glycosylated 
isoforms of the transporters were associated with functional 
activity, but they could not determine in what way N-glycosylation 
affected their activity. Apparently, the absence of the glycan 
trapped the protein in subcellular compartments (57).
Galactose (Gal) and N-acetyl glucosamine (GlcNAc) were also 
found in complex hybrid glycan glycoproteins in a MDR Chinese 
hamster cell line (58). Greer and Ivey (59), using the uterine 
sarcoma human cell line MES-SA/D × 5, identified two different 
complex N-glycans in ABCB1  –  one high mannose, detected 
by Galanthus nivalis agglutinin (GNA), a lectin that binds 
specifically to α-1,3 mannose residues and one branched hybrid 
oligosaccharide – capped with terminal sialic acid units, detected 
by Sambucus nigra (SNA) and Maackia amurensis (MAA), lectins 
with specificity toward α-2,6- and α-2,3-sialic acid residues, 
respectively. Moreover, Datura stramonium (DSA), specific for 
biantennary oligosaccharides possessing β(1–4)-GlcNAc resi-
dues, also recognized the ABCB1 transporter proteins. However, 
there was no evidence of fucose (Fuc) or mannose (Man), and 
little or no detected sialic acids attached to ABCB1 glycoproteins 
in Karnal bunt (KB) cell lines (60). In addition, there is no direct 
evidence of O-linked glycosylation of ABCB1 (59, 61).
Efforts to demonstrate the glycan structures present in 
ABCB1 are complicated by the existence of more than 50 known 
isoforms of this protein, presenting different glycan epitopes. 
Despite this, it was found that in pediatric brain tumors, the 
presence of bisecting GlcNAc in human ABCB1 is correlated 
with tumor progression, showing a potential relevance of gly-
comes of ABCB1 as tumor markers. Another important finding 
in this study was the fact that the binding of the PHA-E, a lectin, 
which has an unusual specificity toward bi- or triantennary 
galactosylated N-glycan with bisecting N-acetylglucosamine, 
was able to subvert chemotherapy resistance in this particular 
case, through inhibition of P-gp activity (62). Since then, other 
works have stated the importance of lectins when it comes to 
drug resistance in cancer. Several studies have pointed out the 
importance of galectins (a lectin family with an affinity for 
β-galactosides) in establishing a resistance phenotype (63–65), 
and many recent papers report the successful use of galectin 
inhibitors in overcoming resistance (66–68).
ePiTHeLiAL-TO-MeSeNCHYMAL 
TRANSiTiON: DiFFeReNCeS BeTweeN 
NORMAL AND CANCeR CeLLS
The EMT process can be induced in several cancer cell lines 
(69–71), usually by TGF-β1 addition or hypoxia, the most com-
mon inducers (72).
Among the changes that epithelial cells go through during 
EMT, alterations in the glycosylation pattern are beginning to 
attract attention from many groups. One of the most well-known 
examples is the glycosylation of E-cadherin (73). E-cadherin 
exhibits four sites for N-linked glycan at 554, 566, 618, and 633 
asparagine residues, carrying usually a bisected mannosyl core, 
born from N-acetyl glucosaminyl transferase III activity (Gnt-III), 
which adds a β-1,4 Man to the α-1,6 Man in the N-glycan core 
(74). Such structure stabilizes homophilic interactions between 
E-cadherin chains and suppresses metastasis (75). Gnt-III com-
petes for its target with Gnt-V, which adds a β-1,6 Man, creating 
a branched structure that can no longer be modified by Gnt-III. 
An atypical prevalence of Gnt-V activity over Gnt-III results in 
tumors with increased mobility and metastatic potential (76).
A more recent paper showed through lectin array and real-
time PCR experiments that the expression of the MAN2A and 
FUCA1 genes, responsible for encoding α-mannosidase 2 and 
Type 1 α-l-fucosidase, respectively, are reduced during EMT 
induced by TGF-β in HCV29 bladder cancer cells (77).
A fibronectin isoform, dubbed oncofetal fibronectin (onfFN), 
for its expression in fetal and cancer tissues, has gained great 
importance during the last few years. The onfFN differs from 
other fibronectin isoforms due to the addition of a O-glycan 
epitope (GalNAcα1-O-Ser/Thr or Galβ1-3GalNAcα1-O-Ser/
Thr) to the IICS domain (17). Its expression is significantly 
increased during TGF-β-induced EMT and is also dependent 
upon GalNAc-T6/T3 activities, glycosyltransferases that add 
N-acetylgalactosamine (GalNAc) residues to serine or threonine. 
In fact, knockdown of either GalNAc-T6 or T3 results in EMT 
inhibition (19). A follow-up study from the same group showed 
that not only the onfFN is capable, by itself, of inducing EMT in 
lung cancer cells but it also presents a synergism with TGF-β1, 
leading to the belief that cells undergoing the transition may 
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secrete onfFN, which once incorporated to the cellular matrix 
may facilitate the process to other cells exposed to lesser concen-
trations of TGF-β1 (20). It is important to note that variation in 
epigenetic patterns lead to heterogeneity, meaning not all cells 
will undergo EMT at the same time and not all that do undergo 
will successfully metastasize. Progenitor cell inherent character-
istics, intra- and extracellular signaling and epigenetics factors 
will together determine whether or not a cell will go through 
EMT and generate metastatic foci (78).
ePiGeNeTiC MODiFiCATiONS  
AND THe MDR PHeNOTYPe
Among neoplasia-associated epigenetic modifications, alterations 
in cellular glycosylation have recently received attention as a key 
factor of neoplastic evolution. Changes in the glycosylation profile 
seem to not only directly influence cell survival and growth but 
also assist tumor-induced immunomodulation and subsequent 
metastasis (79, 80). Similar to that of other genes, the expression 
of genes encoding glycosyltransferases is regulated through both 
transcription factors and epigenetic mechanisms (81). As a result, 
each cell type or tissue has an exclusive set of glycosyltransferases 
that create specific types of glycan structures (82). As mentioned 
above, in transformed cells, the expression of glycosyltransferases 
is often misregulated. In normal mammary epithelial cells, for 
example, while GnT-V/MGAT5 is expressed at very low levels, 
Gnt-III/MGAT3 is highly expressed (83). However, in breast 
epithelial cells undergoing EMT, the DNA hypermethylation in 
promoter CpG islands of MGAT3 gene inhibits its transcriptional 
initiation and results in permanent gene silencing (84). Since the 
methylation status of MGAT5 did not change along EMT (84), it 
might be upregulated by the E26 transformation-specific (ETS) 
transcription factor family through the HER2 pathway, resulting 
in highly branched N-glycan structures on cancer cells (85). It has 
been demonstrated elsewhere that the unusual glycan structures 
generated by Gnt-V activity are able to modulate both the EMT 
process (77, 86, 87) and the gain of an acquired drug-resistant 
phenotype (12, 88–90).
Dynamic signaling interactions between cancer cells and 
their stroma in the tumor microenvironment are able to induce a 
transient and/or resistant state that protect transformed cells by 
inducing an event known as cell adhesion-mediated drug resist-
ance (CAM-DR) (91). This phenomenon might be triggered by 
soluble factors such as cytokines, hormones, and growth factors 
(92, 93) as well as by cell interactions between adjacent cells (94) or 
extracellular matrix components (ECM) (95, 96). Regarding the 
protective effects of ECM components, it has been shown that the 
adhesion of cancer cells to fibronectin, a major ECM component, 
resulted in increased p27kip1 levels, which correlate with cell 
cycle arrest and drug resistance (91). Furthermore, adhesion of 
cancer cells to laminin and collagen IV through beta-1 integrins 
enhanced tumorigenicity and conferred resistance to apoptosis 
induced by standard chemotherapeutic agents (97, 98). Since the 
ECM is composed of various glycoproteins and polysaccharides, 
and in cancer cell, the enzymatic machinery for glycan biosyn-
thesis is dysregulated, it is believable to speculate that changes 
in glycosylation of ECM components are capable of modulating 
both invasiveness and the chemoresistance in cancer cells. New 
experiments need to be performed to confirm such hypotheses.
ATYPiCAL GLYCOSYLATiON,  
eMT, AND MDR
Two different studies, using different models reached contro-
versial results suggesting that EMT might not be required for 
metastasis. Zheng et al. (99), using pancreatic tumors obtained 
from mice that were knockout for either Snail or Twist showed 
that in both cases, cancer cells were as likely to cause metastasis 
as the control tumors, but Snail and Twist deletion made them 
more sensitive to gemcitabine. In a different work, primary breast 
tumors from Tri-PY mice (specifically generated to track EMT 
through fluorescent reporters) overexpressing miR-200, a micro-
RNA capable of regulating ZEB1 and ZEB2, both transcriptional 
repressors of E-cadherin (100), and although these cells were able 
to produce lung metastasis when injected into wild-type mice, 
the metastatic cells have not gone through EMT. Also, in accord-
ance with the work by Zheng et al. (99), the tumors presented 
increased sensitivity to cyclophosphamide (101). It is important 
to bear in mind though, that in those studies, the metastatic foci 
do not originate directly from primary tumors but from cancer 
cells injected directly into the bloodstream, so the importance of 
EMT to metastasis end invasion cannot be completely dismissed. 
A study by Tsou et al. (102) verified that resistance induction on 
MCF-7 cells with adriamycin leads to both loss of E-cadherin 
and gain of N-cadherin expressions. Interestingly, such changes 
are observed alongside other important events, such as loss of 
Bcl-2 and increased levels of P-gp, which are strongly associated 
with the acquisition of the MDR phenotype. Such transforming 
events can be reverted by wortmannin, an inhibitor of PI3K, 
reducing the resistance to doxorubicin as well as the expression 
of Snail, Slug, and Twist, all associated with EMT (103, 104). 
Overexpression of Twist in breast cancer cells has been revealed 
to promote resistance to radiation in MCF-7 cells through the 
disruption of p53 function (105), as well as increase invasiveness, 
motility while mediating resistance to taxol (106–108). Twist 
overexpression also provokes genome instability in MCF-7 cells 
(109). Such instability can not only initiate cancer but also affect 
its progression and prognosis, generating resistance and increas-
ing metastatic potential (110). These results seem to suggest that 
while EMT may not be entirely necessary to metastasis formation, 
it does seem to be intimately related to MDR phenotypes. Thus, 
EMT promoters may prove to be interesting therapeutic targets.
Aside from increased invasiveness, another characteristic 
conferred to cancer cells by a high expression of Gnt-V is resist-
ance to anoikis through activation of the p21-kinase (PAK1), an 
upstream mediator of the EGFR pathway (111, 112). Furthermore, 
overexpression of MGAT5, the gene responsible for Gnt-V, in 
MCF-7 cells, increases resistance to paclitaxel, doxorubicin, and 
vincristine, while its downregulation achieved a higher sensitiv-
ity. Also, in adriamycin-resistant cell line MCF/ADR, expression 
of the MGAT5 gene was three times higher than in the parental 
cell line (89).
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In addition to MGAT5, Ma et  al. (89) also found higher 
levels of ST6Gal I, a glycosyltransferase responsible for adding 
sialic acid to Gal residues in a α-2,6 linkage. Using human 
ovarian cancer cells, Schultz et  al. (113) evinced a direct 
correlation between ST6Gal I expression and resistance to 
cisplatin. Another study using K562 and K562/ADR human 
leukemia cell lines showed similar results, while also shedding 
a light on the mechanism behind the acquired resistance. 
Silencing the ST6Gal I gene on the resistant cell line lead to 
the downregulation of the PI3K/AKT pathway and reduced 
expression of both MRP1 and P-gp, while its overexpression in 
the parental cells achieved the opposite results (114). The PI3K 
activation was already correlated to the MDR phenotype, since 
the pharmacological inhibitor LY294002 is capable of increased 
doxorubicin accumulation in HT29RDB colon carcinoma cells 
by reducing MRP1 expression in the membrane and leading to 
apoptosis (115). A recent study by Meng et al. (116) also cor-
relates ST6Gal I activity to increased mobility and invasiveness 
of osteosarcoma cells. The authors also discovered that silencing 
the sialyltransferase decreased expression of N-cadherin and 
metalloproteinases 2 and 9, as well as other EMT markers. Also, 
the PI3K pathway plays a role in EMT process in different cancer 
cell types (117, 118).
Another study by Ma and collaborators (119) using different 
resistant leukemia cell lines, along with their parent cells, has 
uncovered important differences regarding sialylation patterns 
between adriamycin-resistant cells and their non-resistant 
counterparts. Expression of the ST8Sia IV sialyltransferase was 
elevated in the HL60-ADR, U937-ADR, and NB4-ADR cell lines, 
and its knockdown provoked a reduction in the resistance level. 
On the other hand, overexpression of the ST8Sia IV gene in 
the HL-60 parental cell line leads to increased drug resistance. 
The changes in resistance level are related to alteration in the 
expressions of both ABCB1 and ABCC1 drug transporters, 
through the PI3K/Akt pathway. This type of sialyltransferase is 
involved with polysialic chains and this particular enzyme is 
essential to the expression of the neural cell adhesion molecule 
(NCAM-1). NCAM-1 is indeed involved with chemoresist-
ance mechanisms, but paradoxically, its expression has been 
confirmed to be decreased in resistant neuroblastoma cell lines 
exposed to vincristine or doxorubicin when compared to the 
parental cells (120, 121). The upregulation of NCAM-1 is also 
linked to the decrease of E-cadherin expression during EMT, 
being important for the formation of focal adhesion points and 
integrin-dependent cell mobility (122). Also, its polysialylation 
through ST8Sia 2 or ST8Sia 4 activity has been shown to be 
essential to the onset EMT in NMuMG murine cells, a common 
model for EMT studies (123).
Surprisingly, the same study (119) reveals opposite results for 
ST3Gal V, with its knockdown being associated with increased 
resistance to adriamycin, paclitaxel, and vincristine, while its 
overexpression results in lower resistance levels for the tested 
drugs. The observed results for the two sialyltransferases (ST8Sia 
and ST3Gal V) are diametrically opposed, down to the changes in 
ABCC1 and ABCB1 expression and the involvement of PI3K/Akt 
signaling pathway, which has been well established as important 
to drug resistance mechanisms as well as tumor proliferation 
(115, 124, 125). ST3Gal V is responsible for the synthesis of GM3, 
a ganglioside and common precursor of almost all gangliosides, 
especially from the ganglio-series, by adding a α-2,3-sialic acid 
to lactosilceramide (126). It has been demonstrated before that 
the glucosylation of ceramide and consequent increase in the 
content of glycosphingolipids leads to an increase in ABCB1 
expression though the activation of Src (127). GM3 itself is 
thought to influence the level of ABCB1 phosphorylation, which 
in turn increases drug transport (128). A study by Mathow et al. 
(129) showed that repression of the ST3Gal V gene results in 
increased susceptibility disruption of cell adhesion by TGF-β 
signaling (129), while its upregulation via Zeb1 leads to increased 
cell–cell adhesion.
Fucosylation is another well-studied aspect of glycosylation, 
when speaking of cancer glycophenotypes. It has been described 
that fucosyltransferase 4 (Fut4), Fut6, and Fut8 are increased 
in hepatocellular carcinoma cells exhibiting a MDR phenotype 
dependant upon the PI3K/Akt pathway. Furthermore, reducing 
fucosyltransferases expression leads to abrogation of the resist-
ance phenotype (130). Fut4 also appears to play an important role 
in EMT. A study by Yang et al. (131) confirms that inhibiting the 
expression of the Fut4 in breast cancer cells leads to a reduced 
expression of EMT markers, such as N-cadherin and vimentin, 
as well as an inhibition of the PI3K/Akt pathway. A more recent 
study sheds more light into the involvement of fucosylation. Using 
two different breast cancer cell lines, the authors established that 
miR-224-3p, through the downregulation of the FUT4 gene, 
is capable of reverting the MDR phenotype and of increasing 
sensitivity to taxol, vincristine, and doxorubicin (12). It is also 
worth considering that in addition to the PI3K/Akt, Fut4 also 
activates NF-κB signaling, which just like PI3K is also involved 
in both resistance phenotype by inducing Pg-P expression (132) 
and EMT signaling (133).
Looking over the data, it is easy to see that not only many of 
the glycosylation changes represent common points between cells 
undergoing EMT and cells that have acquired a MDR phenotype 
but also such changes are often necessary for both EMT and 
MDR. To establish such connections is not only important to 
understand the events surrounding metastasis and drug resist-
ance but also to develop ways to circumvent them.
CONCLUSiON
Despite the abundance of data showing that all ABC proteins 
are heavily N-glycosylated, to this date, there is little evidence on 
how, or if at all, changes in these glycan epitopes are capable of 
affecting their transport activity. The exception being for studies 
using broad glycosylation inhibitors that attest the importance of 
glycosylation to protein localization within the cell.
There is, however, a plethora of data demonstrating that 
aberrant glycosylation occurring during cancer development 
affects among other things, drug resistance. Many groups 
have successfully identified, despite some contradictions that 
can be ascribed to the different cell lines and chemotherapy 
drugs used, a number of glycosylation changes that commonly 
appear during several resistance inducing protocols, such as 
higher levels of α-2,6-sialic acid units and altered fucosylation. 
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Many such alterations are also commonly observed in cells 
undergoing EMT.
Given the increasing number of research groups dedicated to 
discovering glycosylation patterns common to different resistant 
cancer cell lines, it will be interesting to see the effect that these 
discoveries will have on cancer diagnosis, prognosis, and treat-
ment in the next few years, as new biomarkers and therapeutic 
targets will be discovered. Certainly, these findings might be 
used to feed further actions to tackle the metastatic and the drug 
resistance phenotypes, the two main obstacles in the war against 
cancer. It is also becoming clearer that EMT and chemotherapy 
resistance not only walk hand in hand but also are joined by 
glycosylation.
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